NASDAQ:BBHVanEck Vectors Biotech ETF Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding VanEck Vectors Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $157.52 -1.45 (-0.91 %) (As of 06/4/2020 04:00 PM ET) Add Compare Share Today's Range$156.94Now: $157.52▼$159.5550-Day Range$136.24MA: $152.36▼$160.9152-Week Range$112.03Now: $157.52▼$164.69Volume36,599 shsAverage Volume28,186 shsMarket Capitalization$456.34 millionP/E RatioN/ADividend Yield0.30%Beta1.13 ProfileAdvanced ChartDividendInstitutional OwnershipHeadlinesOptions ChainSocial Media Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for VanEck Vectors Biotech ETF. Previous Next 2.4 Community Rank Outperform VotesVanEck Vectors Biotech ETF has received 38 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVanEck Vectors Biotech ETF has received 40 “underperform” votes. (Add your “underperform” vote.)Community SentimentVanEck Vectors Biotech ETF has received 51.28% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about VanEck Vectors Biotech ETF and other stocks. Vote “Outperform” if you believe BBH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BBH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 1.7 Dividend Strength Dividend LeadershipVanEck Vectors Biotech ETF is a leading dividend payer. It pays a dividend yield of 0.30%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthVanEck Vectors Biotech ETF does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VanEck Vectors Biotech ETF insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 19.61% of the stock of VanEck Vectors Biotech ETF is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.81 out of 5 stars Basic Details Issuer Van Eck Fund NameVanEck Vectors Biotech ETF Tax ClassificationRegulated Investment Company SymbolNASDAQ:BBH Inception Date12/20/2011 Fund ManagerHao-Hung Peter Liao, Guo Hua Jason Jin WebN/A PhoneN/A Fund Focus Asset ClassEquity BenchmarkMarket Vectors US Listed Biotech 25 Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionGlobal Fund Statistics Assets Under Management$1.92 billion Average Daily Volume$14,048.50 Discount/Premium-1.27% ETF Expenses Management Fee0.35% Other Expenses0.04% Total Expenses0.39% Fee Waiver-0.04% Net Expenses0.35%Administrator, Advisor and Custodian AdministratorVan Eck Associates Corporation AdvisorVan Eck Associates Corporation CustodianThe Bank of New York Mellon Corporation DistributorVan Eck Securities Corporation Transfer AgentThe Bank of New York Mellon Corporation Trustee Lead Market MakerVirtu Financial NASDAQ:BBH Rates by TradingView Receive BBH News and Ratings via Email Sign-up to receive the latest news and ratings for BBH and its competitors with MarketBeat's FREE daily newsletter. VanEck Vectors Biotech ETF (NASDAQ:BBH) Frequently Asked Questions How has VanEck Vectors Biotech ETF's stock been impacted by COVID-19 (Coronavirus)? VanEck Vectors Biotech ETF's stock was trading at $126.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BBH shares have increased by 24.2% and is now trading at $157.52. View which stocks have been most impacted by Coronavirus. Has VanEck Vectors Biotech ETF been receiving favorable news coverage? News articles about BBH stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. VanEck Vectors Biotech ETF earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutVanEck Vectors Biotech ETF. Who are some of VanEck Vectors Biotech ETF's key competitors? Some companies that are related to VanEck Vectors Biotech ETF include Adams Diversified Equity Fund (ADX), PIMCO Corporate&Income Opportunity Fund (PTY), Tri-Continental (TY), Gabelli Equity Trust (GAB), Royce Value Trust (RVT), Hercules Capital (HTGC), Liberty All-Star Equity Fund (USA), Boulder Growth & Income Fund (BIF), Tortoise Energy Infrastructure (TYG), AllianceBernstein Global Hgh Incm Fd (AWF), Tekla Healthcare Investors (HQH), Blackrock Muniyield Insured Fund (MYI), Invesco Van Kampen Munpl Oprtnty Tr (VMO), General American Investors (GAM) and Templeton Global Income Fund (GIM). View all competitors. What other stocks do shareholders of VanEck Vectors Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Vectors Biotech ETF investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Marina Biotech (MRNA), Sanofi (SNY), Cidara Therapeutics (CDTX), Quest Diagnostics (DGX), Crispr Therapeutics (CRSP), Johnson & Johnson (JNJ), Matinas BioPharma (MTNB) and Micron Technology (MU). What is VanEck Vectors Biotech ETF's stock symbol? VanEck Vectors Biotech ETF trades on the NASDAQ under the ticker symbol "BBH." Who are VanEck Vectors Biotech ETF's major shareholders? VanEck Vectors Biotech ETF's stock is owned by many different institutional and retail investors. Top institutional shareholders include Morgan Stanley (1.67%), Morgan Stanley (1.56%), UBS Group AG (1.71%), Murphy Capital Management Inc. (1.38%), Mogy Joel R Investment Counsel Inc. (0.83%) and Envestnet Asset Management Inc. (0.58%). Which institutional investors are selling VanEck Vectors Biotech ETF stock? BBH stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates, Bank of New York Mellon Corp, Mogy Joel R Investment Counsel Inc., Ironsides Asset Advisors LLC, UBS Group AG, Murphy Capital Management Inc., Aspiriant LLC, and Wells Fargo & Company MN. Which institutional investors are buying VanEck Vectors Biotech ETF stock? BBH stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Columbus Macro LLC, PNC Financial Services Group Inc., Advisor Group Holdings Inc., CIBC World Markets Inc., CAPROCK Group Inc., Cambridge Investment Research Advisors Inc., and HighTower Advisors LLC. How do I buy shares of VanEck Vectors Biotech ETF? Shares of BBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is VanEck Vectors Biotech ETF's stock price today? One share of BBH stock can currently be purchased for approximately $157.52. How big of a company is VanEck Vectors Biotech ETF? VanEck Vectors Biotech ETF has a market capitalization of $456.34 million. This page was last updated on 6/4/2020 by MarketBeat.com Staff
